EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Monopar Therapeutics Inc (MNPR) fair value: what the stock is really worth

We calculate from audited financials what Monopar Therapeutics Inc is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US61023L2079

MT Monopar Therapeutics Inc logo Thin data Sep 13, 2026

Monopar Therapeutics Inc

MNPR · US

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $20.54 · Strongly overvalued (−80%)
!Quality 51/100
!Weak Growth
!negative free cash flow
!Mixed vs. peers (4/7)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Monopar Therapeutics Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$123.84 $1.45 Fair Value $20.54 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range $1.45 – $123.84 · fair‑value band $13.55 – $25.67 · the $102.70 price screens above the $20.54 fair value. Dashed = 300-day average. As of Sep 13, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.

Show more

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Stock analysis

Monopar Therapeutics Inc (MNPR) currently trades at $102.70, while our model-based Fair Value estimate is $20.54, implying the stock looks roughly 400.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $13.55 (bear) to $25.67 (bull), the price of $102.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Monopar Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$13.7M in FY2025.

Key figures

Market cap $761M · EPS (TTM) $−1.94 · Return on equity −15.9% · Return on assets (EBIT) −56.6% · Free cash flow −$12.2M · Net cash $61.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 2% below its 52-week high and 252% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −80%, MNPR screens richer than that median.

Fair Value models

Bear $13.55 Fair Value $20.54 Bull $25.67
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $10.29 $13.78 $20.57 51
All 1 models by family
Asset-Based
NCAV (Graham) $10.29 $13.78 $20.57 51

Open the full fair value analysis →

Notify me when MNPR reaches fair value

Put MNPR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 51/100

Of which business quality 57 · Market factors (momentum, volatility) 73

Profitability 0
Margins and returns on capital today
Quality Growth 75
Are margins and returns improving?
Cashflow 63
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 10
Calm price path (market factor)
Momentum 100
Price trend over the last 3–12 months (market factor)
52W Momentum 99
Distance to the 52-week high (market factor)
Net Issuance 100
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MNPR screens 400% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Monopar Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 646 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 58 · Top 25%
Fair Value upside −83% · Bottom 25%
Profitability
Return on assets −12% · Below median
Net margin (TTM) 0% · Below median
Operating margin (TTM) 0% · Above median
Growth and dividend
Revenue growth 0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.28× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.63 $566.09 +10%
Regeneron Pharmaceuticals, Inc REGN $774.11 $1,241 +60%
argenx SE ARGX $984.69 $917.18 −7%
BeOne Medicines AG 688235 ¥247.30 ¥124.62 −50%
Samsung Biologics Co 207940 1,396,000 KRW 1,535,600 KRW +10%
CSL Limited CSL A$174.41 A$191.85 +10%
Alnylam Pharmaceuticals, Inc ALNY $238.27 $211.88 −11%
Royalty Pharma plc RPRX $58.47 $24.22 −59%
Celltrion, Inc 068270 180,300 KRW 74,519 KRW −59%
BioNTech SE BNTX $96.69 $62.63 −35%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Monopar Therapeutics Inc · Fair Value
$20.54 −400%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Monopar Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/MNPR

Frequently asked questions

Is Monopar Therapeutics Inc (MNPR) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of $20.54 versus a price of $102.70, about −80% upside (overvalued).
What is the fair value of MNPR?
Our model-based fair value for Monopar Therapeutics Inc is $20.54 (as of Sep 13, 2026), built from audited fundamentals. The current price: $102.70.
What is the quality score of MNPR?
Monopar Therapeutics Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Monopar Therapeutics Inc (MNPR)?
Our model-based price target is the fair value of $20.54 (as of Sep 13, 2026) from 1 valuation models. Cautious scenario $13.55, optimistic scenario $25.67. It is a calculation from audited fundamentals, not an analyst target.
What is the Monopar Therapeutics Inc stock forecast for 2026?
Our models put fair value at $20.54, about −80% upside versus a price of $102.70 (overvalued). Cautious scenario $13.55, optimistic scenario $25.67. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Monopar Therapeutics Inc (MNPR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Monopar Therapeutics Inc it is $20.54 per share (as of Sep 13, 2026), against a price of $102.70. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Monopar Therapeutics Inc stock overvalued or undervalued in 2026?
As of Sep 13, 2026, MNPR trades above its calculated fair value: price $102.70, fair value $20.54, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MNPR?
No. The price is what the market pays today ($102.70); the fair value is what the company's own numbers justify ($20.54). For Monopar Therapeutics Inc the two are $82.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Monopar Therapeutics Inc worth?
The market values Monopar Therapeutics Inc at about $761M (market capitalisation, as of Sep 13, 2026). Per share that is $102.70; our models calculate a fair value of $20.54 per share.
What do the bullish and bearish scenarios say about MNPR?
Our models span a range for Monopar Therapeutics Inc: cautious scenario $13.55, base $20.54, optimistic $25.67 per share (as of Sep 13, 2026, price $102.70). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Monopar Therapeutics Inc (MNPR)?
Balance-sheet figures for Monopar Therapeutics Inc (as of Sep 13, 2026): return on equity −15.9%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is MNPR from its 52-week high?
Monopar Therapeutics Inc trades at $102.70, about 2% below its 52-week high of $105.00 and 252% above the low of $29.18 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of $20.54 is for.
Which stocks are comparable to Monopar Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Monopar Therapeutics Inc stock attractive at the current price?
The data as of Sep 13, 2026: price $102.70, calculated fair value $20.54 (−80%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MNPR calculated?
We run Monopar Therapeutics Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $20.54, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5 % above its aggregate fair value. Monopar Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Monopar Therapeutics Inc (MNPR)?
The closing price on Sep 17, 2026 was $102.70. Our model-based fair value is $20.54, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Monopar Therapeutics Inc right now?
The price sits above even our optimistic bull case ($25.67). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($13.55 to $25.67) leaves room in how you read the outcome.

Key figures of Monopar Therapeutics Inc

How large is the market capitalisation of Monopar Therapeutics Inc (MNPR)?
The market capitalisation of Monopar Therapeutics Inc is $761M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Monopar Therapeutics Inc (MNPR)?
Earnings per share at Monopar Therapeutics Inc are $−1.94. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Monopar Therapeutics Inc (MNPR)?
The return on equity (ROE) of Monopar Therapeutics Inc is −15.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Monopar Therapeutics Inc (MNPR)?
On an EBIT basis the return on assets of Monopar Therapeutics Inc is −56.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Monopar Therapeutics Inc (MNPR) generate?
The free cash flow of Monopar Therapeutics Inc is −$12.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Monopar Therapeutics Inc (MNPR) hold?
Monopar Therapeutics Inc holds more cash than debt, $61.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Monopar Therapeutics Inc in the live analysis

One click puts Monopar Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.